T.R.F. pharma
ActiveSummary
The computed 12-month bankruptcy probability of T.R.F. pharma is 1.5% (moderate). The 2024 annual accounts show equity of €14k and a net result of €15k. Its solvency ranks better than 83% of 26043 sector peers (fiscal year 2024). The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2024
81
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes
Profitability100
Solvency99
Growth-
Track record67
Bankruptcy probability, 12 months
1.5%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €1k at 30 days acceptable
Liquidity ample (current ratio 3.86; short-term debt: 25.9% of total assets), and 25.9% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Five signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
74.1%
Return on assets
75.9%
Age of the figures
21 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 17-07-2025, 14 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2024
14 d early
← before the deadline
after the deadline →
Checked, nothing found (1)
Financials · fiscal year 2024, micro schema
Equity
€14k
Total assets
€19k
Net result
€15k
Working capital
€14k
Turnover and EBIT margin not published: the micro schema does not require them.
Balance-sheet composition
Equity and liabilities €19k
Equity
€14k
Debt
€5k
Debt finances 25.9% of the balance-sheet total.
Key figures and ratios
Current ratio
3.86
Debt to equity
0.35
ROE
102.5%
ROA
75.9%
Debt ≤ 1 year
€5k
Income taxes
€4k
Filed annual accounts As filed with the NBB · 2024 · 26 lines
Balance sheet
Code2024
Assets
Total assets20/58€19k
Current assets29/58€19k
Amounts receivable within one year40/41€19k
Other amounts receivable41€19k
Equity and liabilities
Total equity and liabilities10/49€19k
Equity10/15€14k
Contributions10/11€500
Profit (loss) carried forward14€14k
Amounts payable17/49€5k
Amounts payable within one year42/48€5k
Trade debts44€53
Suppliers440/4€53
Taxes, remuneration and social security45€4k
Taxes450/3€4k
Other amounts payable47/48€859
Income statement
Code2024
Gross operating margin9900€18k
Operating profit (loss)9901€18k
Financial income75/76B€582
Recurring financial income75€582
Profit (loss) for the period before taxes9903€19k
Income taxes67/77€4k
Profit (loss) for the period9904€15k
Profit (loss) for the period to be appropriated9905€15k
Appropriation of the result
Profit (loss) to be appropriated9906€15k
Profit to be distributed694/7€859
Return on contributions (dividend)694€859
The notes to these accounts (1 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2025
17-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
NBB filing
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Fléron · 1 establishment unit since 2024
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Clos des Coyeûs 84623 FléronGround area
814 m²
Building footprint
86 m²
Volume, LiDAR
565 m³
Parcel 62068A0239/00W000, Wallonia · tallest building 9.1 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
T.R.F. pharma
since 20242.368.791.864
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62068A0239/00W000 | Wallonia | 814 m² | 1 · 86 m² | 9.1 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
PHARMA WILSON
BE 1016.645.518
Montigny-le-Tilleul · Eq €14,234
Apotheker Van De Weghe Karen
BE 0662.425.965
Deinze · Eq €14,250
JETPHARMA
BE 0508.755.793
Jette · Eq €14,285
Sagenex
BE 0460.691.897
Namur · Eq €14,359
ES PHARMA
BE 1009.079.320
Mol · Eq €14,043
Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 1,108 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded23-12-2024
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
Sources
Crossroads Bank for EnterprisesNational Bank · 1 filingAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.